Ropes & Gray advised Mirador Therapeutics, a precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, in an exclusive worldwide license agreement with Kira Pharmaceuticals for antibody KP-301. The agreement announced on July 16 expands Mirador’s immunology portfolio into inflammatory vascular disease.
Under the agreement, Mirador receives exclusive worldwide rights to develop, manufacture and commercialize KP-301 across all indications. Kira will receive $12 million upon signing and is eligible to receive development and sales milestone payments.
The Ropes & Gray team was led by life sciences licensing partner Abby Gregor and included life sciences partner Arthur Mok and life sciences licensing associates Parker Elliot, Amanda White and Zoe Dettelbach.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.